Wacker Chemie closed today at €83.25, with the stock broadly treading water over the past week while still down over the past month and quarter. That muted move sits against a Q3 2026 headline that reads as a profit story again, with net income of €83.6m on €1,465.7m of sales after a run of losses over the last year. Short term traders are reacting to a tired chart, while longer term investors are looking at an unprofitable trailing twelve months, a forecasted earnings recovery and a valuation that screens as inexpensive on price to sales.
Encouraged by the profit return in Wacker Chemie’s latest quarter but concerned about the recent losses and subdued share price action? Compare that setup with our 201 high quality undervalued stocks for ideas that combine recovery potential with stronger recent fundamentals.
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): €1,465.7m vs €1,340.3m (up 9%)
- Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): profit of €83.6m vs loss of €86.1m (swing back to profit)
- Basic EPS (Q3 2026 vs Q3 2025): not disclosed vs loss of €1.73 per share (improved from prior period loss)
- Trailing 12M Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): loss of €268.1m vs loss of €821.1m (narrowed loss over the year)
Management is shifting from heavy investment to higher-margin returns. Ask Charlie what Wacker Chemie’s REFOCUS plan really changes.
Wacker Chemie: Margin Ambitions Meet Early Proof Points
The bullish story hangs on Wacker Chemie turning internal programs into structurally higher profitability rather than waiting for a big polysilicon upswing.
"The main thing that has to go right is that Wacker Chemie delivers the targeted >€300m PACE savings and executes its shift toward higher value silicones and semiconductor polysilicon, while keeping capex in the guided €300 to 400m range."
Q3 gives early evidence this playbook is working. PACE savings of about €145m year to date and more than €60m in Q3 are already lifting EBITDA, with silicones and polymers both reporting stronger earnings helped by pricing and mix. Capex around €300m for 2026 sits squarely inside the guided band, supporting the capital discipline side of the thesis.
The price and this Narrative do not agree. → Uncover what this Narrative says Wacker Chemie is actually worth.
Wacker Chemie: Execution Risk Still Hanging Over Biosolutions
The bearish read focuses on under earning assets and slow progress in newer units at Wacker Chemie.
"the slower than expected ramp of new biotech capacities and the turnaround status of most biosolutions units suggest that any uplift from digitalization could be outweighed by prolonged underutilization and weak revenue contribution from this segment, which would limit group earnings."
Q3 numbers give that concern some backing. Biosolutions delivered €100m of sales and only €8m of EBITDA, with full year profit guided at about €30m. Management explicitly described the division as underperforming potential and still focused on filling capacity, so the earnings drag from sluggish ramp up has not been cleared yet.
Hunt For Quiet Disconnects
Wacker Chemie just showed how a single quarter can look cleaner than the trailing picture. The real opportunity could sit in stocks that look mispriced before consensus catches up.
- Company 1 - 38% below our estimate - refocuses on higher margin civil projects while shedding weaker housing exposure to keep returns supported.
- Company 2 - 32% below our estimate - sells the GPU hardware and software stack many AI data centres already treat as their default choice.
- Company 3 - 26% below our estimate - supplies custom chips and networking gear that large cloud platforms rely on to keep data flowing securely.
Three companies from the same screener. Open every one of the 201 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com